PDE10A and schizophrenia: Both direct and indirect pathways have competing effects on antipsychotic‐like activities and motor functions in rodents.15, 16, 17 Compared to other PDE10A inhibitors, the balanced activation of the direct and indirect pathway MSNs by TAK‐063 may represent a novel therapeutic approach to treat patients with schizophrenia, either alone or in combination with other D2 antagonist antipsychotics.